Plus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Plus Therapeutics's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 24.2% per year.
Key information
-22.9%
Earnings growth rate
87.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -24.2% |
| Return on equity | n/a |
| Net Margin | -271.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating
Oct 07Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end
Sep 22Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02
Jul 21Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems
Dec 21Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?
Aug 25
Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial
Jun 16Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why
May 11Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
May 04Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
Feb 23Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM
Nov 19Revenue & Expenses BreakdownBeta
How Plus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -13 | 9 | 0 |
| 30 Sep 23 | 4 | -15 | 10 | 0 |
| 30 Jun 23 | 3 | -17 | 10 | 0 |
| 31 Mar 23 | 1 | -21 | 10 | 0 |
| 31 Dec 22 | 0 | -20 | 10 | 0 |
| 30 Sep 22 | 0 | -19 | 9 | 0 |
| 30 Jun 22 | 0 | -17 | 8 | 0 |
| 31 Mar 22 | 0 | -15 | 8 | 0 |
| 31 Dec 21 | 0 | -13 | 7 | 0 |
| 30 Sep 21 | 0 | -13 | 7 | 0 |
| 30 Jun 21 | 0 | -11 | 6 | 0 |
| 31 Mar 21 | 0 | -10 | 6 | 0 |
| 31 Dec 20 | 0 | -8 | 6 | 0 |
| 30 Sep 20 | 1 | -4 | 6 | 0 |
| 30 Jun 20 | 6 | -2 | 6 | 0 |
| 31 Mar 20 | 6 | -2 | 5 | 0 |
| 31 Dec 19 | 7 | -4 | 5 | 0 |
| 30 Sep 19 | 7 | -7 | 5 | 0 |
| 30 Jun 19 | 2 | -11 | 5 | 0 |
| 31 Mar 19 | 2 | -9 | 5 | 0 |
| 31 Dec 18 | 3 | -11 | 6 | 0 |
| 30 Sep 18 | 4 | -18 | 7 | 0 |
| 30 Jun 18 | 5 | -19 | 8 | 0 |
| 31 Mar 18 | 6 | -24 | 10 | 0 |
| 31 Dec 17 | 6 | -27 | 11 | 0 |
| 30 Sep 17 | 8 | -23 | 11 | 0 |
| 30 Jun 17 | 9 | -24 | 12 | 0 |
| 31 Mar 17 | 10 | -24 | 12 | 0 |
| 31 Dec 16 | 11 | -22 | 12 | 0 |
| 30 Sep 16 | 12 | -20 | 12 | 0 |
| 30 Jun 16 | 12 | -13 | 12 | 0 |
| 31 Mar 16 | 12 | -2 | 12 | 0 |
| 31 Dec 15 | 12 | -19 | 12 | 0 |
| 30 Sep 15 | 12 | -24 | 14 | 0 |
| 30 Jun 15 | 11 | -34 | 16 | 0 |
| 31 Mar 15 | 9 | -51 | 19 | 0 |
| 31 Dec 14 | 8 | -39 | 22 | 0 |
| 30 Sep 14 | 7 | -42 | 25 | 0 |
| 30 Jun 14 | 9 | -38 | 25 | 0 |
| 31 Mar 14 | 10 | -29 | 25 | 0 |
| 31 Dec 13 | 12 | -26 | 25 | 0 |
| 30 Sep 13 | 16 | -20 | 25 | 0 |
| 30 Jun 13 | 15 | -26 | 25 | 0 |
Quality Earnings: PSTV is currently unprofitable.
Growing Profit Margin: PSTV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PSTV is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.
Accelerating Growth: Unable to compare PSTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PSTV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.